arthron

arthron

[är′thron]
Etymology: Gk
a joint or articulation, including its various components of bones, cartilaginous inserts, all soft tissue structures intervening between the rigid skeletal parts, and the adjacent muscular elements.
References in periodicals archive ?
TTI), a Canadian biopharmaceutical company, today announced that it has acquired all assets belonging to Arthron Ltd.
Arthron owns or controls a large estate of intellectual property related to the activating receptor FcyRIIa, pioneered by Professor Mark Hogarth, currently the director of the Austin Research Institute.
Prima Biomed Limited (ASX: PRR) subsidiary, Arthron Pty Ltd, has direct evidence that the receptor being targeted by Arthron is responsible for the release of key inflammatory chemicals responsible for rheumatoid arthritis.
Arthron has recently demonstrated that activation of its proprietary target, the Fc receptor on white blood cells is a major source of release of high levels of TNFa.
PRIMABioMed Limited (Melbourne, Australia), the cancer and immunotherapy research and therapeutic development company, announced that it has received notification from the United States Patent and Trademark Office that it will allow an application relating to the three dimensional (3D) structure of the Fc receptor (FcR), the target of drugs being developed by its subsidiary Arthron Ltd.
PRIMABioMed Limited , the cancer and immunotherapy research and therapeutic development company, today announced that its subsidiary Arthron Pty Ltd.
Prima Biomed Limited (Melbourne, Australia) announced its subsidiary Arthron Ltd has succeeded in securing an Australian patent protecting the three dimensional structure of its drug target, the Fc receptor (FcR), and use of this structure to design drugs targeted at diseases, such as rheumatoid arthritis, that involve the receptor.
Professor Mark Hogarth, Chief Scientific Officer of Arthron, stated, "TNF Alpha is released by activated inflammatory white blood cells (macrophages) and we have demonstrated that activation of the Fc receptor triggers this release.
Significant success has also been achieved in PRIMA's Arthron drug design program.
PRIMABioMed Limited , the cancer and immunotherapy research and therapeutic development company, today announced that it has received notification from the United States Patent Office that it will allow an application relating to the three dimensional (3D) structure of the Fc receptor (FcR), the target of drugs being developed by its subsidiary Arthron Ltd.
These are valuable assets, which Arthron will be able to leverage in future licensing negotiations.
The Company's Arthron subsidiary, which encompasses compounds developed to combat rheumatoid arthritis (RA), has advanced discussions with several international pharmaceutical companies to secure a sublicensing deal for certain aspects of its technology currently under development.